Table 1.

Relationship of PD-L1 expression by tumor cells and infiltrating immune cells to patient demographics and clinicopathologic features

Tumor cellsInfiltrating immune cells
All patientsPD-L1(−)PD-L1+aPD-L1(−)PD-L1+a
n = 49n = 25n = 24Pbn = 22n = 27Pb
Gender, n (%)
 Female17 (35)8 (32)9 (38)0.7698 (36)9 (33)>0.99
 Male32 (65)17 (68)15 (62)14 (64)18 (67)
Age at primary diagnosis
 Mean (SD)65.94 (12.63)65.52 (12.62)66.38 (12.89)64.23 (12.92)67.33 (12.45)
 Median (range)65 (30,90)70 (42,90)64.5 (30,90)0.73464.5 (42,90)69.5 (30,90)0.329
Pathologic stage at diagnosis, n (%)
 IA19 (39)12 (48)7 (29)0.45710 (45)9 (33)0.593
 IB1 (2)0 (0)1 (4)0 (0)1 (4)
 IIA4 (8)2 (8)2 (8)1 (5)3 (11)
 IIC1 (2)0 (0)1 (4)0 (0)1 (4)
 IIIA8 (16)2 (8)6 (25)2 (9)6 (22)
 IIIB12 (24)7 (28)5 (21)7 (32)5 (19)
 IV4 (8)2 (8)2 (8)2 (9)2 (7)
  • a Tumor cells or associated infiltrating immune cells were considered PD-L1+ if ≥5% of cells had membranous (cell surface) PD-L1 expression. In this table, patients with multiple specimens are considered PD-L1+ if any specimen was positive.

  • bFisher exact test for categorical variables, Wilcoxon–Mann–Whitney test for continuous variables.